Quercetin
Quercetin's Potential in PV and MPNs Emerging research suggests that quercetin, a naturally occurring flavonoid, may hold therapeutic promise for polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs). While clinical trials specifically in PV/MPN patients are lacking, a growing body of preclinical evidence warrants further investigation into quercetin's potential as a complementary treatment. 1. JAK2 Inhibition: In Silico and Preclinical Evidence In silico (computer-based) molecular docking studies have identified quercetin as a potential natural JAK2 inhibitor, with predicted binding affinities in the nanomolar range (Potential JAK2 Inhibitors from Selected Natural Compounds, 2024 ). This suggests that quercetin may directly interfere with JAK2 activity, a key driver of MPN pathogenesis. Numerous in vitro and in vivo studies have demonstrated quercetin's ability to inhibit the JAK/STAT pathway directly or indirectly in various cancer types and tissue model...